(Q48147255)

9 February 2018

title

Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma (English)

1 reference

9 February 2018

author

Maja Bradic Lindh

2

1 reference

9 February 2018

Ola Söderberg

8

1 reference

9 February 2018

Heikki Joensuu

11

1 reference

9 February 2018

Martin Hasselblatt

13

1 reference

9 February 2018

Andreas von Deimling

10

object named as

Andreas von Deimling

1 reference

9 February 2018

4

Marjut Puputti

1 reference

9 February 2018

author name string

Janna Paulsson

1

1 reference

9 February 2018

Malin Jarvius

3

1 reference

9 February 2018

Monica Nistér

5

1 reference

9 February 2018

Nina N Nupponen

6

1 reference

9 February 2018

Werner Paulus

7

1 reference

9 February 2018

Gregor Dresemann

9

1 reference

9 February 2018

Arne Ostman

12

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 April 2011

1 reference

9 February 2018

International Journal of Cancer

published in

1 reference

9 February 2018

volume

128

1 reference

9 February 2018

issue

8

1 reference

9 February 2018

page(s)

1981-1988

1 reference

9 February 2018

Genetic pathways to primary and secondary glioblastoma

cites work

1 reference

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells

21 January 2018

1 reference

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

21 January 2018

1 reference

Characterization of an imatinib-sensitive subset of high-grade human glioma cultures

21 January 2018

1 reference

Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy

21 January 2018

1 reference

Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme

21 January 2018

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

21 January 2018

1 reference

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

21 January 2018

1 reference

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

EGFR antagonists in cancer treatment

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer

21 January 2018

1 reference

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method.

21 January 2018

1 reference

Platelet-derived growth factor receptor expression and activation in choroid plexus tumors

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.25528

1 reference

9 February 2018

1 reference

9 February 2018